Camella is an investor and startup Advisor passionate about bold entrepreneurs developing scientific innovation for the betterment of human health. For over 7 years, she has leveraged her deep technical expertise to invest in companies from Seed to Series B across Healthcare Technology, Tech Bio, Biotech and Diagnostics. She has held several board Director and Observer roles. Before venture capital, Dr. Wilson worked at the Boston Consulting Group, supporting global Biopharma in achieving their strategic and operational goals. As a Postdoctoral Fellow at UCSF, her research focused on uncovering mechanisms of lipid accumulation and inflammation in NAFLD and NASH and developing novel therapies to improve insulin sensitivity. She also supported early-stage catalytic funding and business development efforts for the USCF Catalyst Program, designed to help researchers translate their work into commercially viable products. Her doctoral thesis utilized genetic models to characterize a novel pancreas-derived peptide and its role in hepatic glucose production.Camella holds a Ph.D. in Biochemistry and Molecular Biophysics from the University of Pennsylvania and a B.Sc. in Biochemistry from Temple University. She is a native of St. Vincent & the Grenadines.
